From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors - Scorecard - MDSpire

Utilizing Patient-Derived Tumor Organoids for Tailored Cancer Treatment: Progress in Managing Advanced Solid Tumors

  • By

  • Gang Wang

  • Zhibin Tan

  • Wenting Jia

  • Yuanyuan Liu

  • Huan Wang

  • Wenbo Sun

  • Weiwei Sun

  • Lu Meng

  • Yudong Zhang

  • Ning Liu

  • Feng Li

  • Hongchao Dong

  • July 20, 2026

Share

Clinical Scorecard: Utilizing Patient-Derived Tumor Organoids for Tailored Cancer Treatment: Progress in Managing Advanced Solid Tumors

At a Glance

CategoryDetail
ConditionAdvanced Solid Tumors
Key MechanismsPatient-derived tumor organoids (PDTOs) recapitulate tumor biology and predict treatment responses.
Target PopulationPatients with advanced solid tumors facing treatment resistance.
Care SettingClinical oncology settings utilizing personalized medicine approaches.

Key Highlights

  • PDTOs established with a success rate of 91.5%.
  • PDTO drug sensitivity testing showed 85.0% accuracy in predicting clinical outcomes.
  • Sensitivity of PDTOs was 86.7% and specificity was 80.0%.
  • PDTOs may help overcome multidrug resistance in advanced solid tumors.
  • Further validation through large-scale studies is warranted.

Guideline-Based Recommendations

Diagnosis

  • Utilize PDTOs for predicting treatment responses in advanced solid tumors.

Management

  • Incorporate PDTOs in personalized treatment strategies for advanced solid tumors.

Monitoring & Follow-up

  • Evaluate treatment responses using PDTO-based drug sensitivity testing.

Risks

  • Consider the limitations of current models in predicting drug responses.

Patient & Prescribing Data

Patients with pathologically confirmed advanced solid tumors.

PDTOs can guide individualized treatment regimens based on drug sensitivity.

Clinical Best Practices

  • Implement PDTOs as companion diagnostics in treatment planning.
  • Ensure informed consent is obtained prior to sample collection for organoid establishment.

Related Resources & Content

Original Source(s)

From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors

  • by Gang Wang, Zhibin Tan, Wenting Jia, Yuanyuan Liu, Huan Wang, Wenbo Sun, Weiwei Sun, Lu Meng, Yudong Zhang, Ning Liu, Feng Li, Hongchao Dong

  • July 20, 2026

Related Content

Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management

Long-term risk of gynecologic malignancies in postmenopausal women with vaginal bleeding and benign endometrial lesions: a cohort study

Dual-generative synthesis framework: enhancing polyp segmentation in colonoscopy via mask-conditional GANs